Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Antibody–drug conjugates in colorectal cancer: target biology, resistance, and the clinical-trial landscape

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality, and outcomes in microsatellite-stable metastatic disease have improved only modestly despite optimised cytotoxic, anti-VEGF and anti-EGFR regimens. Antibody–drug conjugates (ADCs) link tumour-associated antigen targeting to intracellular delivery of potent payloads, but their place in CRC is still being defined. We outline core design principles (target/antibody, linker, payload) and summarise clinical experience with constructs of direct or indirect relevance to CRC (trastuzumab deruxtecan, sacituzumab govitecan, trastuzumab emtansine). We then map the global CRC ADC pipeline using Trialtrove Clinical Intelligence and major registries, identifying 214 phase I–III studies. Disease-specific development streams are reviewed, focusing on HER2-, CEACAM5-and TROP2-directed ADCs, combination approaches pairing HER2-directed ADCs with chemotherapy or anti-angiogenic therapy, and next-generation concepts including LGR5-axis targeting and EGFR-based conjugates for stem-like or chemoresistant disease. Finally, we discuss class-wide challenges—treatment-related toxicities, primary and acquired resistance, and the need for harmonised biomarker strategies—and highlight how nanotechnology-enabled delivery and AI-guided target/biomarker optimisation may support more precise deployment. Overall, ADCs are a rational but early-stage option for biomarker-selected CRC, with clear activity in subsets and open questions on dosing, sequencing, combinations and long-term safety.

Related

  1. Antibody–drug conjugates in solid tumors: current landscape, challenges, and future directions
    Teng Yang, Takaya Shimura, Qing Wei +1
    Holistic Integrative OncologyPeer-reviewedCC BYFull textMedical imaging & radiologyDOAJ
  2. Application of antibody-drug conjugates in colorectal cancer
    Huazhong Cai, Jingzhe Li, Qiang Cai +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  3. The immunological landscape of antibody-drug conjugates: from target to payload biology
    Jeremy D. Waight, Maria C. Speranza, Christopher B. Hopson +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textMedical imaging & radiologyCrossrefEurope PMCPMC
  4. Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Molecular and immune-mediated resistance to antibody-drug conjugates in breast cancer
    Alvise Mattana, Chiara Veronese, Julia Penitenti +8
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
BibTeX
@article{chen2026antibodydrug,
  title = {{Antibody–drug conjugates in colorectal cancer: target biology, resistance, and the clinical-trial landscape}},
  author = {Chaofan Chen and Luming Guo and Xu Han and Tingting Deng},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = nov,
  doi = {10.3389/fphar.2026.1967108},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1967108},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Antibody–drug conjugates in colorectal cancer: target biology, resistance, and the clinical-trial landscape
AU  - Chaofan Chen
AU  - Luming Guo
AU  - Xu Han
AU  - Tingting Deng
PY  - 2026
DA  - 2026/11/10
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1967108
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1967108
AB  - Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality, and outcomes in microsatellite-stable metastatic disease have improved only modestly despite optimised cytotoxic, anti-VEGF and anti-EGFR regimens. Antibody–drug conjugates (ADCs) link tumour-associated antigen targeting to intracellular delivery of potent payloads, but their place in CRC is still being defined. We outline core design principles (target/antibody, linker, payload) and summarise clinical experience with constructs of direct or indirect relevance to CRC (trastuzumab deruxtecan, sacituzumab govitecan, trastuzumab emtansine). We then map the global CRC ADC pipeline using Trialtrove Clinical Intelligence and major registries, identifying 214 phase I–III studies. Disease-specific development streams are reviewed, focusing on HER2-, CEACAM5-and TROP2-directed ADCs, combination approaches pairing HER2-directed ADCs with chemotherapy or anti-angiogenic therapy, and next-generation concepts including LGR5-axis targeting and EGFR-based conjugates for stem-like or chemoresistant disease. Finally, we discuss class-wide challenges—treatment-related toxicities, primary and acquired resistance, and the need for harmonised biomarker strategies—and highlight how nanotechnology-enabled delivery and AI-guided target/biomarker optimisation may support more precise deployment. Overall, ADCs are a rational but early-stage option for biomarker-selected CRC, with clear activity in subsets and open questions on dosing, sequencing, combinations and long-term safety.
SN  - 1663-9812
ER  -